Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00162903
Status:
COMPLETED
Last Update Posted:
2005-11-23
First Post:
2005-09-12
Brief Title:
Nitric Oxide Endothelin-1 and the Patency of Ductus Arteriosus in Preterm Infants
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
The Role of Nitric Oxide Endothelin-1 and Inflammatory Mediators in the Patency of Ductus Arteriosus in Preterm Infants
Status:
COMPLETED
Status Verified Date:
2001-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
BACKGROUND Patent ductus arteriosus PDA is a frequent clinical event in preterm infant The cardiopulmonary functions of these preterm babies may be adversely affected by the patency of ductus arteriosus Ductal tissues are sensitive to the constricting effect of endothelin-1 and the dilating effect of prostaglandins inflammatory mediators and concentration of oxygen
OBJECTIVE To examine the role of endogenous nitric oxide NO and endothelin-1 ET-1 in the pathogenesis of patent ductus arteriosus of the preterm infants We hypothesize that the patency of ductus arterious in preterm infants is probably due to inappropriate production of endogenous nitric oxide and the interaction with various inflammatory mediators and prostaglandins which is different from those of term infants In addition the secretion of endothelin is probably decreased The purpose of this study is to monitor the changes of these substance sequentially and to evaluate the relationship among endothelin-1 endogenous nitric oxide and inflammatory mediators in the pathophysiology of patent ductus arteriosus in preterm infants
METHODS AND MATERIALS
1 Inclusion criteria
1 Preterm infants with gestational age less than 32 weeks or birth weight less than 2000 gm
2 Informed consent
2 Numbers of study population
With 80-100 evaluable infants 40-50 patients in PDA and non-PDA groups respectively
3 Blood sample collecting on day 137 after regular echocardiographic evaluation is assessed for inflammatory mediator IL-8 IL-10 nitric oxide metabolites nitrite and nitrate endothelin-1 and cGMP
4 Statistical analysis Student t-test testing the differences of clinical data Wilcoxon signed rank test for comparing data obtained between the PDA and non-PDA patients the PDA patients before and after intravenous indomethacin and those who are responsive or refractory to the therapy
OBJECTIVE To examine the role of endogenous nitric oxide NO and endothelin-1 ET-1 in the pathogenesis of patent ductus arteriosus of the preterm infants We hypothesize that the patency of ductus arterious in preterm infants is probably due to inappropriate production of endogenous nitric oxide and the interaction with various inflammatory mediators and prostaglandins which is different from those of term infants In addition the secretion of endothelin is probably decreased The purpose of this study is to monitor the changes of these substance sequentially and to evaluate the relationship among endothelin-1 endogenous nitric oxide and inflammatory mediators in the pathophysiology of patent ductus arteriosus in preterm infants
METHODS AND MATERIALS
1 Inclusion criteria
1 Preterm infants with gestational age less than 32 weeks or birth weight less than 2000 gm
2 Informed consent
2 Numbers of study population
With 80-100 evaluable infants 40-50 patients in PDA and non-PDA groups respectively
3 Blood sample collecting on day 137 after regular echocardiographic evaluation is assessed for inflammatory mediator IL-8 IL-10 nitric oxide metabolites nitrite and nitrate endothelin-1 and cGMP
4 Statistical analysis Student t-test testing the differences of clinical data Wilcoxon signed rank test for comparing data obtained between the PDA and non-PDA patients the PDA patients before and after intravenous indomethacin and those who are responsive or refractory to the therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None